What are the most common mistakes with ACE-031 (ACVR2B-Fc)?
The most common ACE-031 (ACVR2B-Fc) mistakes are treating it as a drop-in Follistatin replacement (different mechanism, much longer half-life); ignoring the halt history; assuming community-vendor product matches Acceleron's clinical material. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for ACE-031 (ACVR2B-Fc) is limited.
Common ACE-031 (ACVR2B-Fc) mistakes
- Treating it as a drop-in Follistatin replacement (different mechanism, much longer half-life)
- Ignoring the halt history
- Assuming community-vendor product matches Acceleron's clinical material
Bloodwork worth tracking
- CBC if researching
- BUN / creatinine
References
- ACE-031 (soluble activin receptor IIB) increases muscle mass, Phase 1 in postmenopausal women — Attie KM et al., Muscle Nerve, 2013
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial — Campbell C, McMillan HJ, Mah JK, et al., Muscle & Nerve, 2017
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ACE-031 (ACVR2B-Fc)
Full ACE-031 (ACVR2B-Fc) breakdownACE-031 (ACVR2B-Fc) what it's used forACE-031 (ACVR2B-Fc) side effectsACE-031 (ACVR2B-Fc) how to take itACE-031 (ACVR2B-Fc) who should avoid itACE-031 (ACVR2B-Fc) half-lifeACE-031 (ACVR2B-Fc) how long to workACE-031 (ACVR2B-Fc) legal statusACE-031 (ACVR2B-Fc) how it worksAsk the AI Coach
Last updated 2026-06-15.